New Drugs for the Treatment of Lymphoma

Luca Paoluzzi; Yukiko Kitagawa; Matko Kalac; Jasmine Zain; Owen A. O'Connor

doi:10.1016/j.hoc.2008.07.006

New Drugs for the Treatment of Lymphoma

Luca Paoluzzi, Yukiko Kitagawa, Matko Kalac, Jasmine Zain, Owen A. O'Connor

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Historically, most drugs developed for treatment of leukemias, lymphomas, and myeloma had already been studied in the solid tumor setting. Nearly 10 years ago, chronic myelogenous leukemia (CML) forever changed this paradigm. Imatinib showed that it was possible to nullify the pathognomic genetic lesion in a hematologic malignancy. Since the approval of imatinib for CML, a host of new drugs active in blood cancers have emerged. This article highlights some areas of innovative drug development in lymphoma where possible; it emphasizes the biologic basis for the approach, linking this essential biology to the biochemical pharmacology. The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway.

Original language	English (US)
Pages (from-to)	1007-1035
Number of pages	29
Journal	Hematology/Oncology Clinics of North America
Volume	22
Issue number	5
DOIs	https://doi.org/10.1016/j.hoc.2008.07.006
State	Published - Oct 2008
Externally published	Yes

Keywords

Bcl-2
Lymphoma
New drugs
Pralatrexate
Syk

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hoc.2008.07.006

Cite this

@article{c5881cce75fc40d3a4dd87477d69b195,

title = "New Drugs for the Treatment of Lymphoma",

abstract = "Historically, most drugs developed for treatment of leukemias, lymphomas, and myeloma had already been studied in the solid tumor setting. Nearly 10 years ago, chronic myelogenous leukemia (CML) forever changed this paradigm. Imatinib showed that it was possible to nullify the pathognomic genetic lesion in a hematologic malignancy. Since the approval of imatinib for CML, a host of new drugs active in blood cancers have emerged. This article highlights some areas of innovative drug development in lymphoma where possible; it emphasizes the biologic basis for the approach, linking this essential biology to the biochemical pharmacology. The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway.",

keywords = "Bcl-2, Lymphoma, New drugs, Pralatrexate, Syk",

author = "Luca Paoluzzi and Yukiko Kitagawa and Matko Kalac and Jasmine Zain and O'Connor, {Owen A.}",

year = "2008",

month = oct,

doi = "10.1016/j.hoc.2008.07.006",

language = "English (US)",

volume = "22",

pages = "1007--1035",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - New Drugs for the Treatment of Lymphoma

AU - Paoluzzi, Luca

AU - Kitagawa, Yukiko

AU - Kalac, Matko

AU - Zain, Jasmine

AU - O'Connor, Owen A.

PY - 2008/10

Y1 - 2008/10

N2 - Historically, most drugs developed for treatment of leukemias, lymphomas, and myeloma had already been studied in the solid tumor setting. Nearly 10 years ago, chronic myelogenous leukemia (CML) forever changed this paradigm. Imatinib showed that it was possible to nullify the pathognomic genetic lesion in a hematologic malignancy. Since the approval of imatinib for CML, a host of new drugs active in blood cancers have emerged. This article highlights some areas of innovative drug development in lymphoma where possible; it emphasizes the biologic basis for the approach, linking this essential biology to the biochemical pharmacology. The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway.

AB - Historically, most drugs developed for treatment of leukemias, lymphomas, and myeloma had already been studied in the solid tumor setting. Nearly 10 years ago, chronic myelogenous leukemia (CML) forever changed this paradigm. Imatinib showed that it was possible to nullify the pathognomic genetic lesion in a hematologic malignancy. Since the approval of imatinib for CML, a host of new drugs active in blood cancers have emerged. This article highlights some areas of innovative drug development in lymphoma where possible; it emphasizes the biologic basis for the approach, linking this essential biology to the biochemical pharmacology. The article focuses on the many new targets including Syk, Bcl-2, CD-40, and the phosphoinositide-3 kinase/AKT/mammalian target of rapamycin pathway.

KW - Bcl-2

KW - Lymphoma

KW - New drugs

KW - Pralatrexate

KW - Syk

UR - http://www.scopus.com/inward/record.url?scp=54049143335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049143335&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2008.07.006

DO - 10.1016/j.hoc.2008.07.006

M3 - Review article

C2 - 18954749

AN - SCOPUS:54049143335

SN - 0889-8588

VL - 22

SP - 1007

EP - 1035

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 5

ER -

New Drugs for the Treatment of Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this